Susanne Klint

Introduction: Susanne Klint is a prominent inventor based in Stockholm, Sweden, known for her groundbreaking contributions to the field of biotechnology. With three patents to her name, her work focuses on novel methods for treating IL-17A associated conditions. Susanne's innovations have the potential to significantly impact the treatment landscape for various diseases.

Latest Patents: Among Susanne Klint's most recent patents are her advancements in methods of treatment for IL-17A associated conditions. The patents disclose a class of engineered polypeptides that exhibit a strong binding affinity for interleukin-17A (IL-17A). Notably, one of her patented polypeptides includes the sequence EXDXAXXEIXXLPNL XXXQXXAFIXXLXX. These engineered molecules not only serve as potential diagnostic and prognostic tools but also as therapeutic agents in managing IL-17A associated diseases.

Career Highlights: Susanne Klint’s career at Affibody AB has been marked by her dedication to innovation in biotechnology. Her expertise in creating engineered polypeptides demonstrates her commitment to advancing medical treatments. Through her research, she has become an influential figure in the field, pushing the boundaries of what is possible in therapeutic interventions.

Collaborations: Working alongside talented individuals such as Fredrik Frejd and Joachim Feldwisch, Susanne has fostered a collaborative environment that promotes creativity and innovation at Affibody AB. These partnerships have been instrumental in enhancing the quality and scope of her research, ultimately leading to significant advancements in treatment approaches.

Conclusion: Susanne Klint is an inspirational inventor whose work is providing new avenues for treating IL-17A associated conditions. With her keen insights and collaborative spirit, she continues to lead the charge in biotechnology innovation, paving the way for future advancements in medical science.

Profile summary based on public USPTO records.